Mesenchymal stem cell therapy for chronic major ischemic stroke


  • The STARTING-2 study found no evidence to suggest that treatment with intravenous preconditioned autologous mesenchymal stem cells (MSCs) improves 90-day modified Rankin Scale (mRS) outcomes in patients with chronic ischemic stroke.

Why this matters

  • The potential application of stem cell therapy for chronic stroke is of keen interest.
  • A previous incarnation of the STARTING-2 study (STARTING) used fetal bovine serum (FBS) to expand autologous MSCs for treatment but encountered efficacy limitations.
  • Using autologous patient serum rather than FBS to expand MSCs could possibly decrease rates of cell senescence and improve therapeutic efficacy of MSC therapy for chronic stroke.